< 1 minute read
Dec. 20, 2021

 DS96432529: a CDK8 Kinase Inhibitor Intended as a Bone Anabolic Agent

DS96432529

oral CDK8 kinase inhibitor effective in ovariectomized rat model CDK8 identified as MoA after screen Bioorganic & Medicinal Chemistry Letters Daiichi Sankyo Co. Ltd.

drughunter.com
Drug Hunter Team

The Daiichi Sankyo CDK8 kinase inhibitor, DS96432529, is intended to be a bone anabolic agent. The molecule shows preclinical efficacy and synergy with alendronate or parathyroid hormone. The discovery program was initiated well before the likely target (CDK8) was identified and provides an interesting retrospective case study for [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in